By Jeff Overley ( August 20, 2015, 11:12 PM EDT) -- Amgen Inc. and Sandoz Inc. on Thursday asked the full Federal Circuit to revisit a fractured panel decision on key elements of the Affordable Care Act's approval pathway for biosimilars, arguing in competing petitions that information-sharing and advance-notice provisions were interpreted incorrectly....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.